Genotype had an insignificant association with response to nutritional supplementation, according to study findings.
In a retrospective analysis of data from the first AREDS, researchers attempted to gauge whether genotypes at two major loci related to age-related macular degeneration — complement factor H (CFH) and age-related maculopathy susceptibility 2 (ARMS2) — had any significant effect on the relative benefits of AREDS supplements in a subset of patients at high risk for progression to late AMD.
Patients were randomly assigned to one of four AREDS supplement treatment arms: placebo; vitamins C and E, and beta-carotene; zinc or antioxidant plus zinc.
Among the 1,237 patients analyzed, late AMD developed in 385 patients (31.1%). The CFH and ARMS2 genotypes were associated independently with development of late AMD (P = .005 and P < .0001, respectively).
Results showed that the combination of CFH, ARMS2 and treatment with the four different AREDS components produced no statistically significant interaction, according to the researchers.
Disclosure: See the study for a full list of all authors’ relevant financial disclosures.